The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
RX
It’s not brave admitting what happened with my Synairgen investment.
Unlike some others, I can’t see into the future and pharmaceutical trials/drugs can be unpredictable.
Things stacking up nicely here, keep churning the data out and very positive outcomes are likely.
Patience GL
Rx
I get what you’re saying, but this is the pharma industry. Long term viewpoint and investment; I had the same for 3yrs with Synairgen, the next big thing that crashed and burnt many people.
Thankfully I’ve recovered some with Avacta.
Next three months pivotal imo.
GL
Rather than keep moaning about how low the SP is, if you are convinced it is going to the moon just keep buying at every opportunity. Especially when the price is so low.
Buy and wait.
GLA
gmcc
Many thanks.
Nurse
Agreed, ethical indeed.
Must be me, too.
Anything that has the potential to save peoples lives is a ship I would like to be on .
GLA
Excellent interview.
Very clear and concise.
Everything lining up…
Nurse
Yes, a massive fingers crossed that this helps to save lives and improve outcomes for millions of cancer sufferers, worldwide.
If that happens, the financial benefits will arrive, too.
GLA
Great news, there could be worse investigators than:
William D Tap.
GLA
PL
But not at the expense of patient death or misery, hence the ethics.
What you mean this one?
https://www.lse.co.uk/rns/AVCT/notice-of-results-and-investor-presentation-lc8ithfu0nlsmxx.html
What??
That’s funny.
This will be exactly the same information, unless we unearth some more data rich facts by then.
If this is the case, then we would find out first via an RNS.
Viking
It’s such a simple thing to calculate; I’m amazed they didn’t know with the first patient.
CJ
Maybe you need to email the head of comms then for an update. You won’t get much back, as anything price sensitive will need to be RNSsd.
Reminder of what AI said recently:
Next step higher dose concluded by this half year. Next part is dose expansion focus 1/2 cancer types 20 patients for soft tissue sarcoma begins asap later this year. In UK and 2 places being lined up in the US.
Will stay patient and see.
RMF
Agreed, posting the facts rather than garbage.
Some posters expecting RNSs every week and lots of news when lengthy trials are happening.
Good post.
Yes, I’m sure hiring top quality staff is a backwards step.
I’m sure Avacta could reach cutting edge oncology stage paying a few staff the minimum wage:
Loon
Is excellent.
Keep buying, even though mine showed up as a sell earlier.
Intriguing read.
Excellent post, many thanks Mr R.
What a ridiculously stupid post, worst of the short week by far.